immunoglobulin therapy for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 severe or critically meta-analysis
Raman CTRI/2020/06/026222		RCT	immunoglobulin therapy	standard of care	COVID-19 severe or critically	some concern	50/50	suggested	suggested 35.4-fold increase in viral clearance ,viral clearance by day 14 with a moderate degree of certainty due to some concern in risk of bias
Tabarsi IRCT20151227025726N2		RCT	immunoglobulin therapy	standard of care	COVID-19 severe or critically	some concern	52/32	inconclusive	inconclusive 10 % increase in deaths,death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias inconclusive 49 % increase in mechanical ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias inconclusive 44 % decrease in ICU admission (PE) with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 severe or critically meta-analysis